Table 1.
Clinical and demographic characteristics.
| Schizophrenia | Healthy controls | p-value | |
|---|---|---|---|
| (n = 30) | (n = 10) | ||
| Age (years) | 48 (9.0) | 48 (8.7) | 0.99 |
| Sex (males, %) | 17 (57%) | 5 (50%) | 0.73 |
| BMI (kg/m2) | 23 (3.8) | 23 (2.8) | 0.89 |
| PANSS | |||
| PANSS total | 95 (13) | – | – |
| PANSS positive | 21 (4.6) | – | – |
| PANSS negative | 26 (4.9) | – | – |
| PANSS general | 48 (8.4) | – | – |
| DIEPSS | 6.3 (3.8) | – | – |
| CP total | 745 (460) | – | – |
| Disease period | 26 (10) | – | – |
| Antipsychotic drugs | Olanzapine (6 cases) | ||
| Risperidone (6 cases) | |||
| Levomepromazine (5 cases) | |||
| Aripiprazole (5 cases) | |||
| Clozapine (5 cases) | |||
| Haloperidol (4 cases) | |||
| Brexpiprazole (3 cases) | |||
| Quetiapine (3 cases) | |||
| Zotepine (3 cases) | |||
| Asenapine (2 cases) | |||
| Blonanserin (2 cases) | |||
| Fluphenazine (1 cases) |
BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; DIEPSS, Drug Induced Extra-Pyramidal Symptoms Scale; CP total, total dose of chlorpromazine equivalence. Dates were expressed mean(standard deviation).